Dexmedetomidine HCL is a relatively selective alpha2-adrenergic agonist indicated for: Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Dexmedetomidine by continuous infusion not to exceed 24 hours. Sedation of non-intubated patients prior to and/or during surgical and other procedures.
Non-Benzodiazepine Hypnotics and Sedatives
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
\"For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. \"
Co-administration of Dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
Acute cerebrovascular disorders . second- or third-degree AV block (unless pacemaker fitted) . uncontrolled hypotension
Agitation . blood pressure changes . bradycardia . changes in blood sugar . dry mouth .hyperthermia . myocardial infarction . Myocardial ischaemia . nausea . tachycardia . Vomiting
Pregnancy Category C: There are no adequate and well-controlled studies of it use in pregnant women.
Bradycardia, hypotension and cardiac arrest is observed.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)